Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Research advances understanding of hypoxic response

Research advances understanding of hypoxic response

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

Viewpoints: Health care is MIA in the State of the Union; Gingrich's earnings for health views

Viewpoints: Health care is MIA in the State of the Union; Gingrich's earnings for health views

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

New federal drug label recommendations for CKD patients

New federal drug label recommendations for CKD patients

Platelet receptor could help with diseases that impact RBCs

Platelet receptor could help with diseases that impact RBCs

Link between prenatal exposure to armed conflict and birth weight

Link between prenatal exposure to armed conflict and birth weight

Alnylam sues Tekmira over LNP-formulated siRNA molecules

Alnylam sues Tekmira over LNP-formulated siRNA molecules

Researchers discover HS1.2 enhancer as the cause of SLE

Researchers discover HS1.2 enhancer as the cause of SLE

END7 campaign aims to combat seven major NTDs by 2020

END7 campaign aims to combat seven major NTDs by 2020

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

New algorithm could help GPs identify women at risk of early ovarian cancer

New algorithm could help GPs identify women at risk of early ovarian cancer

Mitochondrial dysfunction in tissue stem cells can cause aging-associated degeneration

Mitochondrial dysfunction in tissue stem cells can cause aging-associated degeneration

Acceleron Pharma raises $30 million through private financing

Acceleron Pharma raises $30 million through private financing

Correcting anemia can preserve kidney function in many transplant recipients

Correcting anemia can preserve kidney function in many transplant recipients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.